These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 31698687)

  • 21. From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.
    Brandenburg VM; D'Haese P; Deck A; Mekahli D; Meijers B; Neven E; Evenepoel P
    Pediatr Nephrol; 2016 Feb; 31(2):195-206. PubMed ID: 25735207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
    Clarke BL
    Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aberrant activation of Wnt signaling pathway altered osteocyte mineralization.
    Zhou Y; Lin J; Shao J; Zuo Q; Wang S; Wolff A; Nguyen DT; Rintoul L; Du Z; Gu Y; Peng YY; Ramshaw JAM; Long X; Xiao Y
    Bone; 2019 Oct; 127():324-333. PubMed ID: 31260814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sclerostin blockade promotes bone metastases of Wnt-responsive breast cancer cells.
    Hiraga T; Horibe K; Koide M; Yamashita T; Kobayashi Y
    Cancer Sci; 2023 Jun; 114(6):2460-2470. PubMed ID: 36840409
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling.
    Lin C; Jiang X; Dai Z; Guo X; Weng T; Wang J; Li Y; Feng G; Gao X; He L
    J Bone Miner Res; 2009 Oct; 24(10):1651-61. PubMed ID: 19419300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulation of bone metabolism by Wnt signals.
    Kobayashi Y; Uehara S; Udagawa N; Takahashi N
    J Biochem; 2016 Apr; 159(4):387-92. PubMed ID: 26711238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting WNT signaling in the treatment of osteoporosis.
    Baron R; Gori F
    Curr Opin Pharmacol; 2018 Jun; 40():134-141. PubMed ID: 29753194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanobiological osteocyte feedback drives mechanostat regulation of bone in a multiscale computational model.
    Martin M; Sansalone V; Cooper DML; Forwood MR; Pivonka P
    Biomech Model Mechanobiol; 2019 Oct; 18(5):1475-1496. PubMed ID: 31087221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration.
    Wang FS; Wu RW; Lain WS; Tsai TC; Chen YS; Sun YC; Ke HJ; Li JC; Hwang J; Ko JY
    Bone; 2018 Jul; 112():24-34. PubMed ID: 29653294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
    Poole KE; van Bezooijen RL; Loveridge N; Hamersma H; Papapoulos SE; Löwik CW; Reeve J
    FASEB J; 2005 Nov; 19(13):1842-4. PubMed ID: 16123173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption.
    Xiong L; Jung JU; Wu H; Xia WF; Pan JX; Shen C; Mei L; Xiong WC
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3487-92. PubMed ID: 25733894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Sclerostin in Bone and Ectopic Calcification.
    Maré A; D'Haese PC; Verhulst A
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32366042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LGR4 acts as a key receptor for R-spondin 2 to promote osteogenesis through Wnt signaling pathway.
    Zhu C; Zheng XF; Yang YH; Li B; Wang YR; Jiang SD; Jiang LS
    Cell Signal; 2016 Aug; 28(8):989-1000. PubMed ID: 27140682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sclerostin and Bone Aging: A Mini-Review.
    Hay E; Bouaziz W; Funck-Brentano T; Cohen-Solal M
    Gerontology; 2016; 62(6):618-623. PubMed ID: 27177738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Space flight/bedrest immobilization and bone. Osteocyte as a sensor of mechanical stress and Wnt signal].
    Sakai A
    Clin Calcium; 2012 Dec; 22(12):1829-35. PubMed ID: 23187075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Regulation of bone metabolism by the Wnt signaling pathway].
    Houschyar KS; Tapking C; Duscher D; Harati K; Wallner C; Wagner JM; Maan ZN; Rein S; Chelliah MP; Reumuth G; Grieb G; Siemers F; Lehnhardt M; Behr B
    Handchir Mikrochir Plast Chir; 2019 Aug; 51(4):309-318. PubMed ID: 30278469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wnt signaling: a key regulator of bone mass.
    Baron R; Rawadi G; Roman-Roman S
    Curr Top Dev Biol; 2006; 76():103-27. PubMed ID: 17118265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sclerostin Inhibition: A Novel Target for the Treatment of Postmenopausal Osteoporosis.
    Aditya S; Rattan A
    J Midlife Health; 2021; 12(4):267-275. PubMed ID: 35264832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic Activation of Activin A Signaling Causes Chronic Kidney Disease-Mineral Bone Disorder.
    Sugatani T
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.